Clinical aspects and risk factors of nosocomial Stenotrophomonas maltophilia bacteremia episodes in a Turkish intensive care unit
dc.contributor.author | Tunger O. | |
dc.contributor.author | Vural S. | |
dc.contributor.author | Cetin C.B. | |
dc.contributor.author | Keles G. | |
dc.contributor.author | Borand H. | |
dc.contributor.author | Gazi H. | |
dc.date.accessioned | 2024-07-22T08:23:02Z | |
dc.date.available | 2024-07-22T08:23:02Z | |
dc.date.issued | 2007 | |
dc.description.abstract | Stenotrophomonas maltophilia is an important nosocomial pathogen with increasing frequency in recent years, especially in immunocompromised and clinically debilitated patients. The aim of this study is to describe the characteristics of 35 episodes of S. maltophilia bacteremia at Celal Bayar University hospital in Turkey over a 3-year period from January 2003 to December 2005. Cases were identified with microbiology laboratory records and clinical data were collected from the medical record of each patient. The source of bacteremia was central venous catheter (CVC) in 65.7% (23) and respiratory tract infection in 2.9% (1) of episodes while the source of bacteremia was unknown in 11 (31.4%) episodes of bacteremia. Factors significantly associated with mortality were age of ≥65 years, APACHE score of ≥16, the presence of the total parenteral nutrition, anemia, low creatinine clearance level and shock. The most sensitive antibiotic was found as trimethoprim-sulfamethoxazole (91.4%) in antibiotic susceptibility testing of the isolates. Susceptibilities of piperacillin-tazobactam and netilmicin which frequently used antibiotics as an empirical therapy were 62.8% and 68.6%, respectively. © E.S.I.F.T. srl. | |
dc.identifier.DOI-ID | 10.1179/joc.2007.19.6.658 | |
dc.identifier.issn | 1120009X | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19353 | |
dc.language.iso | English | |
dc.publisher | E.S.I.F.T. srl | |
dc.subject | amikacin | |
dc.subject | antibiotic agent | |
dc.subject | cefepime | |
dc.subject | ceftazidime | |
dc.subject | ceftriaxone | |
dc.subject | ciprofloxacin | |
dc.subject | cotrimoxazole | |
dc.subject | imipenem | |
dc.subject | netilmicin | |
dc.subject | piperacillin plus tazobactam | |
dc.subject | prednisone | |
dc.subject | timentin | |
dc.subject | tobramycin | |
dc.subject | adult | |
dc.subject | aged | |
dc.subject | anemia | |
dc.subject | antibiotic sensitivity | |
dc.subject | article | |
dc.subject | bacteremia | |
dc.subject | central venous catheter | |
dc.subject | clinical feature | |
dc.subject | controlled study | |
dc.subject | creatinine blood level | |
dc.subject | demography | |
dc.subject | disease predisposition | |
dc.subject | female | |
dc.subject | hospital infection | |
dc.subject | human | |
dc.subject | infection risk | |
dc.subject | intensive care unit | |
dc.subject | laboratory test | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | medical record | |
dc.subject | microbiological examination | |
dc.subject | mortality | |
dc.subject | outcome assessment | |
dc.subject | respiratory tract infection | |
dc.subject | risk factor | |
dc.subject | Stenotrophomonas maltophilia | |
dc.subject | total parenteral nutrition | |
dc.subject | Turkey (republic) | |
dc.title | Clinical aspects and risk factors of nosocomial Stenotrophomonas maltophilia bacteremia episodes in a Turkish intensive care unit | |
dc.type | Article |